has invited you to join this group
Exploring controversies in clinical research
Absent quality data, the use of these drugs in management of COVID-19 should be reserved for clinical trials.
How should clinicians navigate clinical uncertainty for patients who are taking angiotensin-converting–enzyme inhibitors or angiotensin-receptor blockers?
New AHA/ASA guidelines based on recent trials give moderate support for treatment of selected late-presenting patients.
Glimepiride, in particular, does not appear to confer excess risk for adverse cardiovascular outcomes.
New data bring new controversy.
International guidelines recommend as-needed inhaled steroids for mild asthma.
No; benefits will outweigh risks for many menopausal patients who, through discussion of research findings and shared decision making, can make informed choices about HT use.
A large randomized trial has shown no association between PPI use and most of the adverse outcomes noted in observational studies.
An expert panel no longer recommends it for everyone: Now clinicians and patients will have to decide on their own.
Several recent studies provide evidence that these tools can be used to avoid imaging in many pregnant patients with suspected PE.
New recommendations for travel vaccines for young children may be confusing for practitioners, but resources are available to help.
The FDA recently issued a new warning on aortic rupture; how should this affect practice?
This drug now is approved to lower cardiovascular risk in selected high-risk patients with atherosclerosis, but potential benefits and harms should be weighed carefully.
Two new studies push the pendulum away from aspirin prophylaxis.